Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
The RESONATE-17 Trial: Efficacy and Safety of Ibrutinib in Patients with Relapsed/Refractory CLL and del17p
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
ONO-4059: A New Oral, Selective BTK Inhibitor for Patients with High-Risk CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read More
Page 206 of 329
203
204
205
206
207
208
209
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma